Latanox

Latanoprost, the active ingredient in Latanox, is a prostaglandin analog presented as eye drops for ocular use. It increases uveoscleral outflow of aqueous humor, thereby lowering intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The company ensures product integrity through stringent temperature‑controlled logistics and full regulatory compliance.

Latanox (latanoprost) is used in the management of ocular conditions that require reduction of intra‑ocular pressure.

- Open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. - Ocular hypertension: reduces eye pressure to prevent development of glaucoma. - Pseudoexfoliative glaucoma: decreases intra‑ocular pressure in this secondary form of glaucoma.

Latanox may cause ocular and systemic adverse reactions; most are mild and reversible.

Common Side Effects: - Eye redness (conjunctival hyperemia). - Eye irritation or foreign‑body sensation. - Increased eyelash growth (hypertrichosis). - Darkening of the iris (brown pigmentation).

Serious or Rare Side Effects: - Uveitis or iritis. - Macular edema.

When prescribing Latanox, clinicians should consider the following precautions to ensure safe use. - Pregnancy: safety not established; use only if potential benefit justifies risk. - Breastfeeding: unknown excretion in milk; weigh benefits against potential risks. - Pre‑existing ocular inflammation: may exacerbate uveitis; monitor closely. - Concomitant ocular surgery: may increase risk of postoperative inflammation; assess need. - Contact lens wearers: may experience deposits on lenses; advise removal before instillation. - Store at below 25°C: keep in original container, protect from light and moisture.

Latanox can interact with other ocular or systemic agents; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Use with other prostaglandin analog eye drops: may increase risk of ocular hyperpigmentation and inflammation. - Combination with intra‑ocular pressure‑lowering surgeries: may cause excessive hypotony.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce prostaglandin efficacy. - Topical corticosteroids: may diminish pressure‑lowering effect. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect, monitor pressure.